ID   Hmel-p16-2
AC   CVCL_VS15
SY   Human melanocytes lacking p16-2
DR   Wikidata; Q94213052
RX   PubMed=12759390;
CC   Sequence variation: Mutation; HGNC; HGNC:1787; CDKN2A; Simple; p.Met53Thr (c.158T>C); ClinVar=VCV001480737; Zygosity=Heterozygous (PubMed=12759390).
CC   Sequence variation: Mutation; HGNC; HGNC:1787; CDKN2A; Simple; p.Asp108Asn (c.322G>A) (p.Arg122Gln, c.365G>A); ClinVar=VCV000216275; Zygosity=Heterozygous (PubMed=12759390).
CC   Derived from site: In situ; Skin; UBERON=UBERON_0002097.
CC   Cell type: Melanocyte of skin; CL=CL_1000458.
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_VS16 ! Q34
SX   Female
AG   28Y
CA   Finite cell line
DT   Created: 25-02-19; Last updated: 19-12-24; Version: 10
//
RX   PubMed=12759390; DOI=10.1093/jnci/95.10.723;
RA   Sviderskaya E.V., Gray-Schopfer V.C., Hill S.P., Smit N.P.,
RA   Evans-Whipp T.J., Bond J., Hill L., Bataille V., Peters G.,
RA   Kipling D., Wynford-Thomas D., Bennett D.C.;
RT   "p16/cyclin-dependent kinase inhibitor 2A deficiency in human
RT   melanocyte senescence, apoptosis, and immortalization: possible
RT   implications for melanoma progression.";
RL   J. Natl. Cancer Inst. 95:723-732(2003).
//